SG11201704829QA - Methods and compositions for treating brain diseases - Google Patents

Methods and compositions for treating brain diseases

Info

Publication number
SG11201704829QA
SG11201704829QA SG11201704829QA SG11201704829QA SG11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA SG 11201704829Q A SG11201704829Q A SG 11201704829QA
Authority
SG
Singapore
Prior art keywords
compositions
methods
brain diseases
treating brain
treating
Prior art date
Application number
SG11201704829QA
Other languages
English (en)
Inventor
Beverly L Davidson
John H Lee
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of SG11201704829QA publication Critical patent/SG11201704829QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201704829QA 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases SG11201704829QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098085P 2014-12-30 2014-12-30
PCT/US2015/068034 WO2016109649A1 (en) 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases

Publications (1)

Publication Number Publication Date
SG11201704829QA true SG11201704829QA (en) 2017-07-28

Family

ID=56285031

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704829QA SG11201704829QA (en) 2014-12-30 2015-12-30 Methods and compositions for treating brain diseases

Country Status (12)

Country Link
US (1) US11612641B2 (zh)
EP (1) EP3240577B1 (zh)
JP (1) JP6782701B2 (zh)
KR (1) KR102618947B1 (zh)
CN (1) CN107405414A (zh)
AU (1) AU2015374043B2 (zh)
BR (1) BR112017013674A2 (zh)
CA (1) CA2971687A1 (zh)
ES (1) ES2962439T3 (zh)
HK (1) HK1245127A1 (zh)
SG (1) SG11201704829QA (zh)
WO (1) WO2016109649A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109407A (zh) 2014-11-14 2017-08-29 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
AU2015374043B2 (en) 2014-12-30 2021-05-13 University Of Iowa Research Foundation Methods and compositions for treating brain diseases
CN110214187B (zh) 2016-05-18 2024-01-30 沃雅戈治疗公司 调节性多核苷酸
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
CL2016003282A1 (es) * 2016-12-21 2017-08-18 Univ Chile Virus aav/igf2, método de tratamiento genético y su uso en enfermedades relacionadas con mal plegamiento de proteínas tal como la enfermedad de huntington
WO2018132791A1 (en) 2017-01-16 2018-07-19 The Regents Of The University Of California Treatment of neurodegenerative conditions by disruption of rhes
SG11201909868YA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050255086A1 (en) 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20050009112A1 (en) 2003-03-07 2005-01-13 Fred Hutchinson Cancer Research Center, Office Of Technology Transfer Methods for identifying Rheb effectors as lead compounds for drug development for diabetes and diseases associated with abnormal cell growth
BRPI0612925A2 (pt) 2005-04-27 2010-12-07 Univ Florida Res Foudation Inc uso de um composto, composição farmacêutica e kit
KR101286870B1 (ko) * 2009-11-30 2013-07-16 (주)아모레퍼시픽 황기 추출물을 포함하는 대사 촉진 조성물
PT2771342T (pt) * 2011-10-28 2016-08-17 Novartis Ag Derivados de purina e o seu uso no tratamento de doença
CA2854225A1 (en) * 2011-11-01 2013-05-10 Children's Medical Center Corporation Co-activation of mtor and stat3 pathways to promote neuronal survival and regeneration
CN106994126A (zh) 2011-11-08 2017-08-01 因特利凯有限责任公司 使用多种药剂的治疗方案
WO2013116691A1 (en) * 2012-02-02 2013-08-08 The Washington University Methods for improving muscle strength
KR101626526B1 (ko) 2014-10-30 2016-06-02 경북대학교 산학협력단 ｈＲｈｅｂ를 유효성분으로 포함하는 허혈성 뇌질환의 예방 또는 치료용 조성물
AU2015374043B2 (en) 2014-12-30 2021-05-13 University Of Iowa Research Foundation Methods and compositions for treating brain diseases

Also Published As

Publication number Publication date
JP6782701B2 (ja) 2020-11-11
EP3240577A4 (en) 2018-07-25
US11612641B2 (en) 2023-03-28
EP3240577A1 (en) 2017-11-08
WO2016109649A1 (en) 2016-07-07
AU2015374043A1 (en) 2017-07-13
CN107405414A (zh) 2017-11-28
KR102618947B1 (ko) 2023-12-27
AU2015374043B2 (en) 2021-05-13
JP2018502112A (ja) 2018-01-25
BR112017013674A2 (pt) 2018-02-06
HK1245127A1 (zh) 2018-08-24
EP3240577B1 (en) 2023-07-05
CA2971687A1 (en) 2016-07-07
KR20170098931A (ko) 2017-08-30
ES2962439T3 (es) 2024-03-19
US20180000907A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
IL283561B (en) Methods for treating eye diseases
HK1232141A1 (zh) 用於治療亨廷頓病的方法和組合物
ZA201705673B (en) Methods for treating skin
IL252159B (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
HK1225305A1 (zh) 治療腦疾病的方法和組合物
IL246791A0 (en) Compositions and methods for treating eye diseases
HK1246179A1 (zh) 治療視網膜疾病的方法
HK1254432A1 (zh) 用於治療纖維性疾病的方法和組合物
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
HK1245127A1 (zh) 治療腦疾病的方法和組合物
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
HK1258994A1 (zh) 用於疾病治療的方法
ZA201606673B (en) Compositions and methods for treating neurodegenerative diseases
EP3164132A4 (en) Methods and compositions for treating diseases and conditions
HK1246206A1 (zh) 用於治療青光眼的組合物和方法
AP2017009724A0 (en) Methods and compositions for treating hiv-related disorders
IL252904A0 (en) Methods and factors for treating diseases
HK1244782A1 (zh) 用於治療疾病和病癥的組合物和方法
HK1243937A1 (zh) 治療疾病的方法
GB201521083D0 (en) Compositions for treatment and methods thereof
SG10201400823PA (en) Therapeutic methods and compositions for treating diabetes